Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
J Med Microbiol ; 73(2)2024 Feb.
Article in English | MEDLINE | ID: mdl-38362908

ABSTRACT

Introduction. Infectious gastroenteritis is a common reason for consulting a physician. Although most cases of gastrointestinal illness are self-limiting, the identification of the etiologic pathogen by stool specimen analysis is important in cases of more severe illness and for epidemiological reasons.Due to the broad range of causative pathogens, the conventional examination of a stool specimen is labour-intensive and usually requires different diagnostic methods. Multiplex PCR tests [e.g. BioFire Gastrointestinal (GI) Panel] allow the rapid detecting of up to 22 pathogens in one test.Hypothesis. Using a multiplex PCR panel to test stool specimens for infectious gastroenteritis pathogens can improve the detection rate, reduce the time-to-result and hands-on time and lower the costs of a microbiology laboratory.Aim. This study was aimed at evaluating the detection rate, the workflow and associated costs of stool specimen management using the BioFire GI Panel versus conventional methods.Methodology. Stool specimens were evaluated prospectively during the routine operation. Pathogen detection rate, hands-on time, time-to-result and material and personnel costs were determined for the BioFire GI Panel and conventional methods-the latter based on physician request and excluding viral testing.Results. Analysing 333 specimens collected between 2019 and 2020, the detection rate of enteropathogens was significantly higher with a positivity rate of 39.9 % using the multiplex PCR panel compared with 15.0 % using the conventional methods. The BioFire GI Panel presented results in a median time of 2.2 h compared with 77.5 h for culture and 22.1 h for antigen testing, noting that no tests were performed at weekends except for toxinogenic Clostridioides difficile. Based on list prices, the BioFire GI Panel was nine times more expensive compared with conventional methods, whereas hands-on-time was significantly lower using the BioFire GI Panel.Conclusion. Multiplex PCR panels are valuable tools for laboratory identification of infectious agents causing diarrhoea. The higher costs of such a multiplex PCR panel might be outweighed by the higher detection rate, ease of handling, rapid results and most likely improved patient management. However, these panels do not provide information on antimicrobial susceptibility testing. Therefore, if this is necessary for targeted therapy or if outbreak monitoring and control is required, specimens must still be cultured.


Subject(s)
Gastroenteritis , Multiplex Polymerase Chain Reaction , Humans , Workflow , Molecular Diagnostic Techniques/methods , Gastroenteritis/diagnosis , Gastroenteritis/microbiology , Diarrhea , Feces/microbiology
2.
Microbiol Spectr ; 10(5): e0169722, 2022 10 26.
Article in English | MEDLINE | ID: mdl-36190424

ABSTRACT

Multidrug-resistant (MDR) Pseudomonas aeruginosa increasingly causes health care-associated infections. In this study, we determined the activity of ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol against 223 MDR P. aeruginosa clinical isolates recovered from 2013 to 2017 at the University Hospital Frankfurt by using MIC test strips. Furthermore, we evaluated the presence of genes encoding major ß-lactamases, such as VIM, IMP, NDM, GIM, SPM, and KPC; the extended spectrum ß-lactamase (ESBL)-carbapenemase GES; and the virulence-associated traits ExoS and ExoU, as in particular ExoU is thought to be associated with poor clinical outcome. For MDR P. aeruginosa isolates, the MIC50/MIC90 values of ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol were 8/>256 mg/L, 16/>256 mg/L, and 0.25/1 mg/L, respectively. Cefiderocol showed the highest susceptibility rate (97.3%) followed by ceftazidime-avibactam (48.4%) and ceftolozane-tazobactam (46.6%). In 81 (36.3%) isolates, carbapenemase gene blaVIM was detected, and in 5 (2.2%) isolates, blaGES was detected (with a positive association of exoU and blaVIM). More than half of the isolates belong to the so-called international P. aeruginosa "high-risk" clones, with sequence type 235 (ST235) (24.7%) being the most prevalent. This study underlines that ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol are important options for the treatment of infections due to MDR P. aeruginosa, with cefiderocol currently being the most active available antipseudomonal ß-lactam agent. According to our clinical experience, the outcome of cefiderocol therapy (8 patients) was favorable especially in cases of MDR P. aeruginosa-associated complicated urinary tract infections. IMPORTANCE After testing ceftolozane-tazobactam, ceftazidime-avibactam, and cefiderocol against a collection of 233 multidrug-resistant (MDR) Pseudomonas aeruginosa, we showed that cefiderocol is the most active antipseudomonal ß-lactam agent (susceptibility rates were 46.6%, 48.4%, and 97.4%, respectively). The most prevalent one was sequence type 235 (ST235) (24.7%), followed by ST244, ST175, and ST233, with all belonging to the top 10 P. aeruginosa high-risk clones with worldwide distribution. Our data indicate that during surveillance studies special attention should be paid to the MDR and highly virulent VIM- and ExoU-producing variant of ST235. Furthermore, in the case of infections caused by carbapenemase-producing MDR P. aeruginosa, cefiderocol is the preferred treatment option, while outcomes of complicated urinary tract infections and hospital-acquired pneumonia with cefiderocol were favorable.


Subject(s)
Pseudomonas Infections , Pseudomonas aeruginosa , Humans , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , beta-Lactamases/genetics , Ceftazidime/pharmacology , Ceftazidime/therapeutic use , Cephalosporins/pharmacology , Cephalosporins/therapeutic use , Drug Resistance, Multiple, Bacterial , Hospitals , Microbial Sensitivity Tests , Pseudomonas aeruginosa/genetics , Pseudomonas Infections/drug therapy , Tazobactam/pharmacology , Tazobactam/therapeutic use , Cefiderocol
3.
Pneumologie ; 72(5): 347-392, 2018 May.
Article in German | MEDLINE | ID: mdl-29758578

ABSTRACT

Cystic Fibrosis (CF) is the most common autosomal-recessive genetic disease affecting approximately 8000 people in Germany. The disease is caused by mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene leading to dysfunction of CFTR, a transmembrane chloride channel. This defect causes insufficient hydration of the epithelial lining fluid which leads to chronic inflammation of the airways. Recurrent infections of the airways as well as pulmonary exacerbations aggravate chronic inflammation, lead to pulmonary fibrosis and tissue destruction up to global respiratory insufficiency, which is responsible for the mortality in over 90 % of patients. The main aim of pulmonary treatment in CF is to reduce pulmonary inflammation and chronic infection. Pseudomonas aeruginosa (Pa) is the most relevant pathogen in the course of CF lung disease. Colonization and chronic infection are leading to additional loss of pulmonary function. There are many possibilities to treat Pa-infection. This is a S3-clinical guideline which implements a definition for chronic Pa-infection and demonstrates evidence-based diagnostic methods and medical treatment for Pa-infection in order to give guidance for individual treatment options.


Subject(s)
Cystic Fibrosis Transmembrane Conductance Regulator/genetics , Cystic Fibrosis/diagnosis , Cystic Fibrosis/therapy , Practice Guidelines as Topic , Pseudomonas aeruginosa/isolation & purification , Cystic Fibrosis/complications , Cystic Fibrosis/microbiology , Cystic Fibrosis Transmembrane Conductance Regulator/metabolism , Germany , Humans , Pseudomonas Infections/diagnosis
4.
J Antimicrob Chemother ; 73(8): 2047-2053, 2018 08 01.
Article in English | MEDLINE | ID: mdl-29684150

ABSTRACT

Objectives: Aspergillus fumigatus is the most prevalent filamentous fungus in the respiratory tract of patients with cystic fibrosis (CF). The aim of this prospective multicentre study was to investigate the prevalence of azole-resistant A. fumigatus (ARAF) in respiratory secretions from CF patients across Germany and to characterize ARAF isolates by phenotypic and molecular methods. Methods: Twelve tertiary care centres from Germany participated in the study. In total, 2888 A. fumigatus isolates from 961 CF patients were screened for ARAF by using azole-containing agar plates. Antifungal susceptibility testing of isolates was performed by broth microdilution according to EUCAST guidelines. Analysis of mutations mediating resistance was performed using PCR and sequencing of the cyp51A gene. Furthermore, genotyping by microsatellite PCR was performed. Results: Of a total of 2888 A. fumigatus isolates, 101 isolates from 51 CF patients were found to be azole resistant (prevalence per patient 5.3%). The Essen centre had the highest prevalence (9.1%) followed by Munich (7.8%), Münster (6.0%) and Hannover (5.2%). Most ARAF isolates (n = 89) carried the TR34/L98H mutation followed by eight G54E/R, one TR46/Y121F/T289A and one F219S mutation. In two isolates no mutation was found. Genotyping results showed no major clustering. Forty-five percent of CF patients with ARAF had previously received azole therapy. Conclusions: This is the first multicentre study analysing the prevalence of ARAF isolates in German CF patients. Because of a resistance rate of up to 9%, susceptibility testing of A. fumigatus isolates from CF patients receiving antifungal treatment should be part of standard diagnostic work-up.


Subject(s)
Antifungal Agents/pharmacology , Aspergillus fumigatus/drug effects , Azoles/pharmacology , Cystic Fibrosis/microbiology , Drug Resistance, Fungal , Adult , Aspergillus fumigatus/genetics , Aspergillus fumigatus/isolation & purification , Cytochrome P-450 Enzyme System/genetics , DNA Mutational Analysis , Female , Fungal Proteins/genetics , Genotype , Germany , Humans , Male , Microbial Sensitivity Tests , Microsatellite Repeats , Mycological Typing Techniques , Prevalence , Prospective Studies
6.
Euro Surveill ; 20(26)2015 Jul 02.
Article in English | MEDLINE | ID: mdl-26159310

ABSTRACT

Multidrug-resistant organisms (MDRO) and in particular multidrug-resistant Gram-negative organisms (MRGN) are an increasing problem in hospital care. However, data on the current prevalence of MDRO in long-term care facilities (LTCFs) are rare. To assess carriage rates of MDRO in LTCF residents in the German Rhine-Main region, we performed a point prevalence survey in 2013. Swabs from nose, throat and perineum were analysed for meticillin-resistant Staphylococcus aureus (MRSA), perianal swabs were analysed for extended-spectrum beta-lactamase (ESBL)-producing organisms, MRGN and vancomycin-resistant enterococci (VRE). In 26 LTCFs, 690 residents were enrolled for analysis of MRSA colonisation and 455 for analysis of rectal carriage of ESBL/MRGN and VRE. Prevalences for MRSA, ESBL/MRGN and VRE were 6.5%, 17.8%, and 0.4%, respectively. MRSA carriage was significantly associated with MRSA history, the presence of urinary catheters, percutaneous endoscopic gastrostomy tubes and previous antibiotic therapy, whereas ESBL/MRGN carriage was exclusively associated with urinary catheters. In conclusion, this study revealed no increase in MRSA prevalence in LTCFs since 2007. In contrast, the rate of ESBL/MRGN carriage in German LTCFs was remarkably high. In nearly all positive residents, MDRO carriage had not been known before, indicating a lack of screening efforts and/or a lack of information on hospital discharge.


Subject(s)
Bacterial Infections/epidemiology , Cross Infection/epidemiology , Drug Resistance, Multiple, Bacterial , Health Facilities , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Vancomycin-Resistant Enterococci/isolation & purification , Anti-Bacterial Agents/therapeutic use , Bacteria/drug effects , Bacteria/isolation & purification , Bacterial Infections/microbiology , Cross Infection/microbiology , Female , Germany/epidemiology , Humans , Long-Term Care , Male , Methicillin-Resistant Staphylococcus aureus/drug effects , Nose/microbiology , Oropharynx/microbiology , Prevalence , Rectum/microbiology , Risk Factors , Vancomycin Resistance , Vancomycin-Resistant Enterococci/drug effects , beta-Lactamases
7.
Pulm Med ; 2015: 698460, 2015.
Article in English | MEDLINE | ID: mdl-25633889

ABSTRACT

[This corrects the article DOI: 10.1155/2014/621342.].

8.
Pulm Med ; 2014: 621342, 2014.
Article in English | MEDLINE | ID: mdl-24800072

ABSTRACT

There are no European recommendations on issues specifically related to lung transplantation (LTX) in cystic fibrosis (CF). The main goal of this paper is to provide CF care team members with clinically relevant CF-specific information on all aspects of LTX, highlighting areas of consensus and controversy throughout Europe. Bilateral lung transplantation has been shown to be an important therapeutic option for end-stage CF pulmonary disease. Transplant function and patient survival after transplantation are better than in most other indications for this procedure. Attention though has to be paid to pretransplant morbidity, time for referral, evaluation, indication, and contraindication in children and in adults. This review makes extensive use of specific evidence in the field of lung transplantation in CF patients and addresses all issues of practical importance. The requirements of pre-, peri-, and postoperative management are discussed in detail including bridging to transplant and postoperative complications, immune suppression, chronic allograft dysfunction, infection, and malignancies being the most important. Among the contributors to this guiding information are 19 members of the ECORN-CF project and other experts. The document is endorsed by the European Cystic Fibrosis Society and sponsored by the Christiane Herzog Foundation.


Subject(s)
Cystic Fibrosis/surgery , Lung Transplantation/standards , Contraindications , Extracorporeal Circulation/standards , Graft Rejection/prevention & control , Humans , Lung Transplantation/adverse effects , Lung Transplantation/methods , Nutrition Therapy/standards , Patient Education as Topic , Postoperative Care/standards , Preoperative Care/standards , Psychology , Social Support , Tissue and Organ Procurement/organization & administration
9.
J Hosp Infect ; 79(4): 297-301, 2011 Dec.
Article in English | MEDLINE | ID: mdl-22018814

ABSTRACT

Staphylococcus aureus carriage increases the risk of infection. Demographic and microbiological data from adult patients with nasal S. aureus carriage were analysed in order to define effect modifiers of this association. Predictors for growth of S. aureus from clinical cultures were identified in a case-control study using bivariate and multi-variate logistic regression analysis. Between 1 January 2005 and 1 April 2009, 645 patients with nasal S. aureus colonization and documented follow-up of ≥90 days were identified; 159 (25%) patients were found to carry meticillin-resistant S. aureus (MRSA). The median age of patients was 58 years, and 421 (65%) were male. During the subsequent 90 days, one or more clinical cultures were positive for S. aureus in 131 patients (20%). Multi-variate analysis identified a prior history of any S. aureus positive culture [adjusted odds ratio (aOR) 2.4, 95% confidence interval (CI) 1.5-3.8; P=0.0005) as an independent predictor of subsequent S. aureus infection. MRSA colonization was a predictor of infection in patients aged >40 years (aOR 2.5, 95% CI 1.4-4.1; P=0.0004), and even more so in patients aged ≤40 years (aOR 12.4, 95% CI 3.0-51; P=0.0005). Age >40 years was an additional independent risk factor for meticillin-susceptible S. aureus carriers (aOR 3.0, 95% CI 1.2-7.8; P=0.02) but not for MRSA carriers. Preferential screening of patients at high risk for MRSA carriage and subsequent infection, as well as the absence of a universal policy for the use of decolonization regimens, may partly explain the relatively high risk of S. aureus infection in the patient population. MRSA carriers and older patients with recurrent S. aureus positive cultures may gain the greatest benefit from routine decolonization measures.


Subject(s)
Carrier State/epidemiology , Carrier State/microbiology , Nasal Cavity/microbiology , Staphylococcal Infections/epidemiology , Staphylococcus aureus/isolation & purification , Academic Medical Centers , Adult , Age Factors , Case-Control Studies , Female , Humans , Incidence , Male , Methicillin Resistance , Middle Aged , Risk Assessment
10.
J Hosp Infect ; 77(3): 267-70, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21216034

ABSTRACT

We experienced a hospital outbreak of Burkholderia contaminans (Burkholderia cepacia Group K) in a German university hospital with two campuses. Cases were defined as the microbiological detection of B. cepacia complex (BCC) in any clinical specimen sent to the laboratory during 30 June to 21 October 2008. Species identification of BCC was performed by recA gene sequencing, followed by pulsed-field gel electrophoresis (PFGE; SpeI digest) for clonal identity. In total, 61 BCC-positive cases were diagnosed at the two campuses. At least nine patients contracted a ventilator-associated pneumonia with BCC. One patient suffered an infection of a pacing wire insertion site and four patients had septicaemia. Sixteen patients died in hospital, none thought to be due to the outbreak strain. BCC was eventually found in packages of moist prefabricated washcloths used for intensive care patients. German healthcare authorities were informed and a Europe-wide alarm (RAPEX) was initiated through the systems to prevent infections in other hospitals. PFGE proved clonal identity between isolates from clinical specimens and washcloths of both campuses. After elimination of the contaminated washcloths no further cases occurred. This example of a relatively newly introduced product raises the question of whether current regulations are adequate to protect consumers. For critically ill patients, care products should be carefully evaluated. In case of infections due to contaminated products, immediate communication to healthcare authorities is required, including RAPEX warning if products are sold across Europe.


Subject(s)
Bedding and Linens/microbiology , Burkholderia Infections/epidemiology , Burkholderia cepacia complex/isolation & purification , Cross Infection/epidemiology , Disease Outbreaks , Equipment Contamination , Adult , Aged , Aged, 80 and over , Burkholderia Infections/microbiology , Burkholderia cepacia complex/classification , Cross Infection/microbiology , Female , Germany/epidemiology , Hospitals, University , Humans , Male , Middle Aged , Young Adult
11.
Euro Surveill ; 15(43)2010 Oct 28.
Article in English | MEDLINE | ID: mdl-21087580

ABSTRACT

The rapid identification of the potentially toxigenic Corynebacterium species, C. diphtheriae, C. ulcerans and C. pseudotuberculosis is essential for diagnosis and treatment of diphtheria and diphtheria-like diseases. We used matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry (MALDIT-OF MS) in comparison with classical microbiological and molecular methods on 116 Corynebacterium strains. All 90 potentially toxigenic Corynebacterium strains collected by the German National Consiliary Laboratory on Diphtheria in a period of more than ten years were correctly identified by MALDI-TOF MS. We propose an algorithm for fast and reliable diagnosis of diphtheria incorporating MALDI-TOF MS, real-time tox PCR and Elek testing.


Subject(s)
Bacteriological Techniques/methods , Corynebacterium/isolation & purification , Diphtheria Toxin/analysis , Diphtheria/diagnosis , Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization/methods , Algorithms , Corynebacterium/chemistry , Corynebacterium/classification , Diphtheria/microbiology , Germany , Humans , Laboratories , Polymerase Chain Reaction
13.
J Laryngol Otol ; 123(11): 1252-7, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19250590

ABSTRACT

OBJECTIVE: We report an extremely rare case of otitis media due to Francisella tularensis, complicated by multiple suppurative cervical lesions and a lasting conductive hearing loss. CASE REPORT: A young woman presented with otitis media, several neck swellings and a retropharyngeal swelling. Polymerase chain reaction testing of aspirated fluid and serology confirmed the diagnosis of tularaemia. Specific antibiotic therapy initiated six weeks after the onset of initial symptoms did not resolve the disease, and open surgical drainage was necessary. CONCLUSIONS: Otitis media unresponsive to conventional therapy and accompanied by unusually pronounced lymphadenopathy should prompt the clinician to consider tularaemia as a differential diagnosis, in order to initiate timely, specific therapy.


Subject(s)
Otitis Media/diagnosis , Retropharyngeal Abscess/diagnosis , Tularemia/diagnosis , Adult , Female , Francisella tularensis/isolation & purification , Hearing Loss, Conductive/microbiology , Humans , Otitis Media/etiology , Retropharyngeal Abscess/complications , Tomography, X-Ray Computed , Treatment Outcome , Tularemia/complications
14.
Trans R Soc Trop Med Hyg ; 102 Suppl 1: S40-1, 2008 Dec.
Article in English | MEDLINE | ID: mdl-19121684

ABSTRACT

A 62-year-old German patient with insulin-dependent diabetes and diverticulitis was hospitalized for abdominal pain of the left lower quadrant. Further examination revealed an abdominal abscess, which was punctured. Presumptively a Pseudomonas species was identified, but further examination revealed Burkholderia pseudomallei as the causative agent. Most probably this infection was acquired in 1996 during a trip to Thailand, where the patient had been hospitalized. After combined chemotherapy and surgical revision of the abscess, the patient's condition improved. Clinicians and microbiologists have to keep in mind that in some tropical infections such as melioidosis relapse may occur after such a long time.


Subject(s)
Abdominal Abscess/diagnosis , Burkholderia pseudomallei/isolation & purification , Melioidosis/diagnostic imaging , Burkholderia pseudomallei/genetics , Early Diagnosis , Germany , Humans , Middle Aged , Recurrence , Thailand , Travel , Ultrasonography
15.
Eur J Clin Microbiol Infect Dis ; 25(1): 25-30, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16402226

ABSTRACT

The determination of synergistic effects of antimicrobial drug combinations can lead to improved therapeutic options in the antibiotic treatment of cystic fibrosis patients who are chronically infected with multiresistant Pseudomonas aeruginosa isolates. The aim of this study was to evaluate the performance of the E test versus the standard agar dilution checkerboard susceptibility test in the assessment of synergy and, in addition, to determine the activity of two antimicrobial combinations against 163 multiresistant P. aeruginosa isolates from cystic fibrosis patients. The agreement between the checkerboard method and the E test was excellent (>90%) for nonmucoid as well as mucoid isolates from cystic fibrosis patients. The rate of synergy was higher for the antibiotic combination of ceftazidime and tobramycin (28.8% of the cystic fibrosis strains) than for the combination of meropenem and tobramycin (19.0%). However, the probability of synergy for the second antibiotic combination increased significantly when the synergy of the first antibiotic combination had already been demonstrated (Fischer's exact test, p=0.049). The results show that the E test is a valuable and practical method for routine microbiological diagnostics and can aid in the selection of improved antibiotic options in the treatment of cystic fibrosis patients chronically infected with P. aeruginosa.


Subject(s)
Anti-Bacterial Agents/pharmacology , Cystic Fibrosis/complications , Microbial Sensitivity Tests/standards , Pseudomonas Infections/complications , Pseudomonas aeruginosa/drug effects , Anti-Bacterial Agents/therapeutic use , Ceftazidime/pharmacology , Ceftazidime/therapeutic use , Cystic Fibrosis/microbiology , Drug Resistance, Multiple/drug effects , Drug Synergism , Drug Therapy, Combination , Humans , Meropenem , Microbial Sensitivity Tests/methods , Pseudomonas Infections/drug therapy , Pseudomonas Infections/microbiology , Pseudomonas aeruginosa/isolation & purification , Reproducibility of Results , Thienamycins/pharmacology , Thienamycins/therapeutic use , Tobramycin/pharmacology , Tobramycin/therapeutic use
16.
MMW Fortschr Med ; 147(4): 38-40, 2005 Jan 27.
Article in German | MEDLINE | ID: mdl-15745340

ABSTRACT

The pathogenesis of lung infections in patients with mucoviscidosis (cystic fibrosis, CF) is multifactorial. Both host- and pathogen-related factors are involved. The most important germ in terms of progression and pulmonary damage is Pseudomonas aeruginosa. However, the clinical relevance of other CF-typical pathogens has not yet been determined with certainty, and must be assessed on the basis of the clinical presentation of the individual case. To ensure optimal patient management, a CF-specific microbiological diagnostic work-up is mandatory. Since ever more patients now survive into adulthood, the problems associated with chronic infection are gaining in importance. In light of increasing multiresistance, the use of inhalation antibiotics, as well as combined antibiotic treatment, is becoming more and more determinative for the therapeutic outcome.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Bacterial Infections/drug therapy , Cystic Fibrosis/microbiology , Administration, Inhalation , Adult , Anti-Bacterial Agents/administration & dosage , Bacterial Infections/diagnosis , Chronic Disease , Cystic Fibrosis/complications , Cystic Fibrosis/diagnosis , Cystic Fibrosis/drug therapy , Drug Therapy, Combination/administration & dosage , Drug Therapy, Combination/therapeutic use , Gram-Negative Bacterial Infections , Gram-Positive Bacterial Infections , Humans , Prognosis , Pseudomonas Infections/diagnosis , Pseudomonas Infections/drug therapy , Radiography, Thoracic , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapy
17.
J Clin Microbiol ; 39(7): 2717-8, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11427604

ABSTRACT

A total of 137 sputa from 95 consecutive cystic fibrosis (CF) patients undergoing routine bacteriological surveillance were analyzed for Pneumocystis carinii colonization using nested PCR. Seven of 95 patients (7.4%) were PCR positive, suggesting that P. carinii carriage may exist among CF patients due to their underlying pulmonary disease.


Subject(s)
Carrier State/microbiology , Cystic Fibrosis/microbiology , Pneumocystis Infections/microbiology , Pneumocystis/isolation & purification , Polymerase Chain Reaction/methods , Adult , DNA, Fungal/analysis , Female , Humans , Male , Pneumocystis/genetics , Sputum/microbiology
19.
Microb Pathog ; 29(6): 329-43, 2000 Dec.
Article in English | MEDLINE | ID: mdl-11095918

ABSTRACT

The ExoS regulon of Pseudomonas aeruginosa encodes diverse type III secreted effector proteins which have been shown to exert cytotoxic effects in cell culture experiments. However, little information exists about the environmental conditions and stimuli for upregulation of the ExoS regulon. Translational reporter fusion proteins of exoenzyme (Exo) S, ExoT and ExoU, as well as the type II secreted exotoxin A (ETA) to the green fluorescent protein (GFP), were constructed in order to compare exoprotein production under diverse growth conditions. Reporter protein activity was recorded by FACS-analysis and by conventional and confocal laser scanning microscopy. Low ion concentration induced co-ordinated upregulation of ExoS, ExoT and ExoU with a maximum effect at 37 degrees C. A dose-dependent upregulation was seen with human serum or increasing NaCl concentrations. A type III secretion-negative pcrD mutant of P. aeruginosa showed a weak ExoS response to environmental stimuli, compared with the parental strain, suggesting a negative regulatory mechanism. Co-culture with the mammalian cell lines J774A.1 or HeLa led to rapid upregulation of ExoS, ExoT and ExoU synthesis. These data suggest that the ExoS regulon of P. aeruginosa can be triggered by a variety of environmental signals as well as by cell contact with eukaryotic cells.


Subject(s)
ADP Ribose Transferases , Bacterial Toxins , Protein Kinases/biosynthesis , Pseudomonas aeruginosa/pathogenicity , Regulon/physiology , Virulence Factors , Bacterial Proteins/biosynthesis , Bacterial Proteins/genetics , Blotting, Southern , Coculture Techniques , Conjugation, Genetic/physiology , DNA Primers/chemistry , Electrophoresis, Polyacrylamide Gel , Exotoxins/biosynthesis , Exotoxins/genetics , Flow Cytometry , Green Fluorescent Proteins , HeLa Cells , Histidine Kinase , Humans , Immunoblotting , Indicators and Reagents/chemistry , Luminescent Measurements , Luminescent Proteins/chemistry , Microscopy, Confocal , Microscopy, Fluorescence , Mutation , Plasmids/chemistry , Polymerase Chain Reaction , Protein Kinases/chemistry , Protein Kinases/genetics , Pseudomonas aeruginosa/chemistry , Pseudomonas aeruginosa/genetics , Signal Transduction , Pseudomonas aeruginosa Exotoxin A
20.
J Clin Microbiol ; 38(2): 818-25, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10655391

ABSTRACT

We report on the rapid and specific detection of bacteria commonly isolated from clinical specimens from cystic fibrosis (CF) patients by fluorescent in situ hybridization (FISH). On the basis of comparative sequence analysis, we designed oligonucleotide probes complementary to species-specific 16S rRNA regions of these microorganisms and demonstrated the specificities of the probes by hybridization of different remotely related as well as closely related reference strains. Furthermore, in a pilot project we investigated 75 sputum samples and 10 throat swab specimens from CF patients by FISH and detected Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, Haemophilus influenzae, and Staphylococcus aureus within these specimens. The specificity of FISH was 100% in comparison to the results of conventional microbial culture. In contrast, the sensitivity of standard laboratory cultivation was moderately higher, since the limit for microscopic detection of bacteria within sputum samples by FISH was approximately 4 x 10(5) CFU/ml of sputum (resulting in a 90% sensitivity for FISH). Moreover, we demonstrated that FISH will be useful for the rapid detection of bacteria that cause acute pulmonary exacerbations in CF patients, as demonstrated in patients with H. influenzae, S. aureus, and P. aeruginosa exacerbations. Therefore, FISH is a valuable additional method for the rapid and specific detection of bacteria in clinical samples from CF patients, in particular, patients with pulmonary exacerbations.


Subject(s)
Bacteria/isolation & purification , Cystic Fibrosis/microbiology , In Situ Hybridization, Fluorescence , Pharynx/microbiology , Respiratory Tract Infections/diagnosis , Sputum/microbiology , Adult , Bacteria/genetics , Child, Preschool , Colony Count, Microbial , Culture Media , Cystic Fibrosis/complications , Female , Haemophilus influenzae/genetics , Haemophilus influenzae/isolation & purification , Humans , Oligonucleotide Probes , Pilot Projects , Pseudomonas aeruginosa/genetics , Pseudomonas aeruginosa/isolation & purification , RNA, Ribosomal, 16S/genetics , Respiratory Tract Infections/microbiology , Species Specificity , Staphylococcus aureus/genetics , Staphylococcus aureus/isolation & purification
SELECTION OF CITATIONS
SEARCH DETAIL
...